ArticleClinical genetics2012
Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing.
Article in Clinical genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.Frontiers in pharmacology · 2024Article
- Maturing pharmacogenomic factors deliver improvements and cost efficiencies.Cambridge prisms. Precision medicine · 2023Review
- Patients' Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review.Journal of personalized medicine · 2022Article
- Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021Review
- Knowledge and attitudes on pharmacogenetics among pediatricians.Journal of human genetics · 2020Article
- Prescriber Attitudes Toward Implementation of Pharmacogenomic Testing in a Family Medicine Residency Program.PRiMER (Leawood, Kan.) · 2018Article
- Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients.Journal of personalized medicine · 2017Article
- Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience.Pharmacogenomics · 2017Article
- Disease-drug database for pharmacogenomic-based prescribing.Clinical pharmacology and therapeutics · 2016Article
- Are physicians prepared for whole genome sequencing? a qualitative analysis.Clinical genetics · 2016Article
- Pharmacogenomics in the clinic.Nature · 2015Review
- An inter-professional approach to personalized medicine education: one institution's experience.Personalized medicine · 2015Article
- "Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing.The Permanente journal · 2015Article
- Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas.Pharmacogenomics · 2015Article
- Key challenges for next-generation pharmacogenomics: Science & Society series on Science and Drugs.EMBO reports · 2014Article
- Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine?Genetics in medicine : official journal of the American College of Medical Genetics · 2013Article
- Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Pharmacogenomics · 2013Article
- Molecular genetic testing and the future of clinical genomics.Nature reviews. Genetics · 2013Review
- Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional.Pharmacogenomics · 2013Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
Pharmacogenetic (PGx) testing aims to improve therapeutic outcomes through tailoring treatment based on a patient's genetic risk for non-response and/or an adverse event. Given their expertise, geneticists could facilitate the use of PGx testing; however, the preparedness and perceived role of the clinical genetics community is unclear. To assess the attitudes, preparedness, and perceived roles of geneticists in the delivery of PGx testing, we conducted a survey of 1500 randomly selected board-certified genetic counselors and clinical geneticists in the United States [response rate: 37.8% (n = 516)]. Twelve percent of genetic counselors and 41% of clinical geneticists indicated that they had ordered or coordinated patient care for PGx testing, a seemingly high proportion at this early stage of adoption. Almost all respondents had some education on pharmacogenetics, although only 28% of counselors and 58% of clinical geneticists indicated they felt well-informed about PGx testing. About half of counselors (52%) and clinical geneticists (46%) felt they would play 'some' role in the delivery of PGx testing; 17 and 19%, respectively, felt that they would play 'no' or 'a little' role. At this early stage of PGx testing, the role of geneticists and genetic counselors is unclear. However, their experience may aid in readying PGx testing and informing delivery strategies into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.